MARKET

DVAX

DVAX

Dynavax Technolo
NASDAQ
11.69
-0.19
-1.60%
After Hours: 11.69 0 0.00% 19:43 02/03 EST
OPEN
11.64
PREV CLOSE
11.88
HIGH
12.02
LOW
11.64
VOLUME
1.48M
TURNOVER
0
52 WEEK HIGH
17.48
52 WEEK LOW
7.26
MARKET CAP
1.49B
P/E (TTM)
5.83
1D
5D
1M
3M
1Y
5Y
Jim Cramer On This Stock Up 2% Over 6 Months: 'You've Got A Real Winner There'
Benzinga · 01/20 14:01
GNOM: Healthcare Dashboard For January
Seeking Alpha · 01/19 14:00
JMP Securities Keeps Their Buy Rating on Dynavax (DVAX)
TipRanks · 01/11 15:05
H.C. Wainwright Reaffirms Their Buy Rating on Dynavax (DVAX)
TipRanks · 01/10 11:15
Dynavax Technologies' Preliminary Q4, Full-Year 2022 Revenue for Heplisav-B and CpG 1018 Show Gains
Dynavax Technologies' Preliminary Q4, Full-Year 2022 Revenue for Heplisav-B and CpG 1018 Show Gains
MT Newswires · 01/09 09:15
Ardelyx: The Journey Continues
Seekingalpha · 12/29/2022 21:01
Insider Sell: Dynavax Technologies
Insider Sell: Dynavax Technologies
MT Newswires · 12/08/2022 16:51
Implied Volatility Surging for Dynavax Technologies (DVAX) Stock Options
Investors need to pay close attention to Dynavax Technologies (DVAX) stock based on the movements in the options market lately.
Zacks · 12/02/2022 13:46
More
About DVAX
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing vaccines. The Company's products include HEPLISAV-B and CpG 1018. The HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. HEPLISAV-B is a sterile solution for injection presented in 0.5 mL single-dose prefilled syringes. The Company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. The Company is also engaged in developing CpG 1018 as a vaccine adjuvant through research collaborations and partnerships. HEPLISAV-B combines 1018, a toll-like receptor (TLR9) agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). It is primarily focused on adjuvanted vaccines for coronavirus disease (COVID-19), plague, Tdap, seasonal influenza, universal influenza, and shingles.

Webull offers kinds of Dynavax Technologies Corp stock information, including NASDAQ:DVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DVAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DVAX stock methods without spending real money on the virtual paper trading platform.